- Home
- News
- latamerica
- infusion continuous
Infusion Continuous Articles & Analysis
5 news found
Starton Therapeutics Inc., (the “Company”) a clinical stage biotechnology company announced today results from a 28-day efficacy study of STAR-LLD continuous subcutaneous (SC) infusion versus intraperitoneal (IP) lenalidomide in immunomodulatory drug (IMiD)-resistant RPMI CB.17 SCID mice. ...
“The study results also established the compatibility and utility of the continuous ambulatory infusion device with our proprietary subcutaneous formulation. ...
Starton Therapeutics Inc., a clinical stage biotechnology company announced today that the Independent Data Monitoring Committee reviewed the totality of the safety data from the first two cohorts and recommended advancement to the third- and final dose escalation, where subjects will receive the highest infusion strength of STAR-LLD. The ongoing Phase 1 STAR-LLD clinical trial ...
Starton Therapeutics Inc., a clinical stage biotechnology company provides updates on its first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide, in healthy subjects. Four subjects in the first cohort received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour ...
Interestingly, enhancing the natural pulsatile release of GH has been shown clinically in short-term studies to be more efficacious in inducing lipolysis than continuous infusions of GH. The primary endpoints will be to determine the changes in both intrahepatic lipid content and hepatic inflammation and fibrosis with growth hormone (GH) augmentation as measured ...